Photodynamic Therapy for Malignant Brain Tumors
1Department of Neurosurgery, Tokyo Medical University.
Neurologia Medico-Chirurgica
|February 19, 2016
Summary
Photodynamic therapy (PDT) shows promise for treating malignant brain tumors, offering a less invasive approach. Clinical studies demonstrated significant progression-free and overall survival rates in glioblastoma patients, with mild side effects.
Area of Science:
- Oncology
- Neurosurgery
- Photomedicine
Background:
- Photodynamic therapy (PDT) using talaporfin sodium and semiconductor laser is approved for early-stage lung cancer in Japan.
- The potential of PDT for controlling malignant brain tumor invasion was hypothesized.
- Previous research established PDT's efficacy in preclinical glioma models.
Purpose of the Study:
- To evaluate the efficacy and safety of talaporfin sodium-based PDT as an intraoperative therapy for malignant brain tumors.
- To assess patient survival outcomes and treatment-related adverse events.
Main Methods:
- An investigator-initiated clinical study involving 27 patients with malignant brain tumors was conducted.
- Efficacy analysis included 22 patients, focusing on progression-free survival (PFS) and overall survival (OS).
- Safety analysis assessed adverse events directly related to PDT.
Main Results:
- For 13 newly diagnosed glioblastoma patients, median PFS was 12 months, PFS at the irradiation site was 20 months, 1-year survival was 100%, and median OS was 24.8 months.
- Adverse events directly related to PDT were mild in all 27 patients.
- PDT received approval for intraoperative therapy for malignant brain tumors in Japan in September 2013.
Conclusions:
- Talaporfin sodium-based PDT is a safe and effective intraoperative therapy for malignant brain tumors, particularly glioblastoma.
- PDT offers a less invasive, tumor cell-selective treatment option for infiltrated functional brain areas.
- Ongoing post-marketing investigations and educational initiatives promote the safe implementation of PDT.
